查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細胞健康篩查市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190262

細胞健康篩查市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Cellular Health Screening Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，細胞健康篩查市場預計將以 8% 的複合年增長率增長。

COVID-19 在研究期間對市場增長產生了重大影響。 在大流行期間，全球人口對預防衛生意識的提高正在推動市場的增長。 根據 2022 年 6 月發表的 NCBI 論文，過去 12 個月進行的最常見測試是血壓測量 83%、血糖水平 66.2%、尿檢 53.1% 和體液檢查 55.1%。我來了。 預計大流行期間進行的大量預防性檢查將有助於市場增長。 此外，即使在大流行之後，由於人們對預防醫學的興趣日益濃厚，對細胞學的需求也不會下降，預計這將有助於未來五年的市場增長。

市場的增長歸因於細胞健康篩查在個性化醫療中的應用越來越廣泛，以及政府對預防醫學的興趣日益濃厚。 細胞健康篩查在個性化醫療中的潛在應用為該領域的市場參與者提供了重要的增長機會。 隨著老年人口的迅速增加，預計在預測期內對細胞篩選的需求將會增加。 根據世界衛生組織 2021 年 10 月的報告，到 2030 年，地球上將有六分之一的人超過 60 歲。 60 歲及以上的人口預計將從 2020 年的 10 億增長到 2050 年的 14 億。 到 2050 年，世界 60 歲以上人口將翻一番，達到 21 億。 2020 年至 2050 年間，80 歲及以上的人口數量預計將增加兩倍，達到 4.26 億。 隨著人口老齡化的加劇，它變得更容易患上慢性病，從而增加了對預防性診斷的需求，尤其是細胞健康篩查。

此外，慢性病負擔的增加和細胞生物標誌物意識的提高也有望促進市場增長。 根據 Globocan 2020 情況說明書，全球估計有 19,292,789 例新診斷的癌症病例。 此外，據國際癌症研究機構 (IARC) 估計，到 2040 年，全球癌症負擔預計將上升至 2750 萬新發癌症病例。 由於需要有效的早期診斷，癌症等慢性病的增加推動了對細胞健康篩查的需求，預計將有助於預測期內的市場增長。

因此，上述因素預計將在預測期內推動市場增長。 然而，與樣品運輸相關的風險預計將在預測期內抑制增長。

細胞健康篩查的市場趨勢

在預測期內，端粒檢測領域預計將佔據重要的市場份額

預計端粒檢測領域將主導市場。 這些panel將被用於獲取更準確的信息，並幫助進行細胞健康篩查測試以測量端粒長度，從而預防疾病，從而在細胞健康篩查市場中佔據更大的份額。 此外，隨著老年人口的增加，端粒測試的偏好預計會增加，因為它有助於個人檢查他們的細胞年齡，從而採取預防措施，從而促進市場的增長。

根據 2021 年 1 月發表的 Frontiers 研究，端粒是使用最廣泛的衰老分子生物標誌物。 為了提高用於確定端粒長度的方法的靈敏度、可重複性和通量，單細胞端粒測量技術和基於 DNA 甲基化的端粒長度估計方法旨在識別極短的端粒。創新方法，如 基於端粒的測試的此類應用以及靈敏度提高的端粒測試的開發預計將在預測期內促進該部門的增長。

市場參與者為滿足日益增長的端粒檢測需求而增加的活動（例如產品發布）預計也將促進該細分市場的增長。 例如，2021 年 8 月，TruDiagnostics 為其表觀遺傳測試服務 TruAge 發布了一個新的報告擴展。 這種擴展允許根據甲基化準確估計端粒長度。 因此，上述因素預計將在預測期內促進該部門的增長。

北美有望在預測期內主導細胞健康篩查市場

由於患者數量眾多且疾病流行率不斷上升，預計北美將佔據細胞健康篩查市場的很大份額。

根據 Globocon 2020，2020 年美國將有 2,281,658 名新診斷的癌症患者。 在所有癌症中，乳腺癌的發病率最高，為 253,465 例，其次是肺癌（227,875 例）、前列腺癌（209,512 例）和結腸癌（101,809 例）。 此外，根據美國癌症協會2022年公佈的數據，2022年美國總共將新增190萬癌症患者確診。 慢性病的這種增加預計將推動對細胞健康篩查的需求，從而實現有效的早期診斷，從而促進市場增長。

此外，美國疾病控制與預防中心 (CDC) 於 2022 年 7 月更新的數據顯示，冠心病是美國 20 歲及以上成年人最常見的心髒病類型。約有 2010 萬人們已被證明患有這種疾病。 根據 CDC 2022 年 10 月的數據，每 40 秒就有一人心髒病發作，美國每年有近 805,000 人心髒病發作。 因此，心血管疾病的高負擔要求提供細胞健康篩查以進行早期診斷，從而推動市場增長。

細胞健康篩查市場競爭分析

由於多家公司在全球和區域開展業務，細胞健康篩查市場呈碎片化狀態。 全球參與者包括 Bio-Reference Laboratories Inc.、Genova Diagnostics、Immundiagnostik AG、Quest Diagnostics、SpectraCell Laboratories Inc. 和 Telomere Diagnostics Inc. 等公司。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 擴大細胞健康篩查在個性化醫療中的應用
    • 提高政府對預防保健的關注
  • 市場製約因素
    • 與運輸樣品相關的風險
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按類型
    • 單個測試面板
      • 端粒測試
      • 氧化應激測試
      • 炎症測試
      • 重金屬檢測
    • 多測試面板
  • 按樣本類型
    • 血樣
    • 尿樣
    • 其他樣本類型
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Bio-Reference Laboratories, Inc.（OPKO Health）
    • Genova Diagnostics
    • Immundiagnostik AG
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics
    • Segterra Inc.
    • SpectraCell Laboratories Inc.
    • Telomere Diagnostics Inc.

第7章 市場機會與今後動向

簡介目錄
Product Code: 67413

The cellular health screening market is expected to register a CAGR of 8% over the forecast period.

COVID-19 has had a significant impact on the growth of the market over the study period. The rise in preventive health awareness among the global population during the pandemic drives the growth of the market. According to the NCBI article published in June 2022, the most common tests performed in the past 12 months were 83% of blood pressure measurements, 66.2% of blood sugar, 53.1% of urinalysis, and 55.1% of liquid panel. The high number of preventive health screenings during the pandemic is expected to contribute to the growth of the market. In addition, the demand for cellular health screening is expected to remain undisturbed during the post-pandemic period owing to the rising preference for preventive healthcare, thereby contributing to the growth of the market over the coming five years.

The growth of the market is attributed to rising applications of cellular health screening in personalized medicine and increasing government focus on preventive healthcare. The potential applications of cellular health screening in personalized medicine have provided significant growth opportunities to market players in this field. Along with the rapidly growing geriatric population, the demand for cellular screening is expected to rise during the forecast period. According to the World Health Organization Report in October 2021, by 2030, one of every six people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and up is expected to triple, reaching 426 million. The growing geriatric population is more prone to chronic diseases, and thus, this increases the demand for preventive diagnostics, particularly cellular health screening.

Furthermore, the rising chronic illness burden and increasing awareness regarding cellular biomarkers are expected to contribute to the growth of the market. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to increase to 27.5 million new cancer cases worldwide. Such an increase in chronic diseases, such as cancer, is expected to drive the demand for cellular health screening owing to the demand for effective and early diagnosis, thereby contributing to the growth of the market over the forecast period.

Thus, the above-mentioned factors are expected to drive the growth of the market over the forecast period. However, the risks associated with the transport of samples are expected to restrain the growth during the forecast period.

Cellular Health Screening Market Trends

Telomere Tests Segment is Expected to Hold Significant Market Share Over the Forecast Period

The telomere test segment is expected to dominate the market. It accounts for a larger share of the cellular health screening market as these panels are used to get more accurate information and help perform cellular health screening tests to measure the length of the telomere, thereby preventing diseases. Furthermore, with the rising geriatric population, the preference for telomere tests is expected to rise as it facilitates individuals to check their cellular age and thereby take preventive measures, contributing to the growth of the market.

According to the Frontiers research study published in January 2021, telomere had been the most widely used molecular biomarker of aging. Innovative approaches, such as single-cell telomere measurement techniques aimed at the identification of critically short telomeres and DNA methylation-based methods of telomere length estimation, were being developed to improve sensitivity, repeatability, and throughputs of methods used for determining telomere lengths. Such uses of telomere-based tests and developments of improved sensitivity telomere tests are expected to contribute to the growth of the segment over the forecast period.

The rise in the market player's activities, such as product launches, in order to meet the growing demand for telomere tests is expected to contribute to the growth of the segment. For instance, in August 2021, TruDiagnostics released a new report expansion for TruAge, its epigenetic testing service. This expansion gives an accurate estimation of telomere length based on methylation. Thus, the above-mentioned factors are expected to contribute to the growth of the segment over the forecast period.

North America is Expected to Dominate the Cellular Health Screening Market Over the Forecast Period

North America is expected to hold a significant share of the cellular health screening market owing to a high patient pool and rising disease prevalence.

According to Globocon 2020, new cancer cases were diagnosed in 2,281,658 in United States in 2020. Among all cancers, breast cancer had the highest incidence rate, with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809). Also, the data published by the American Cancer Society in 2022 estimated that a total of 1.9 million new cancer cases would occur in United States in 2022. Such increasing incidence of chronic diseases among the population is expected to drive the demand for cellular health screening owing to the effective and early diagnosis, thereby contributing to the growth of the market.

In addition, the Centres for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease was the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in United States. Per the CDC data in October 2022, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of cellular health screening for early diagnosis, driving the market's growth.

Cellular Health Screening Market Competitive Analysis

The cellular health screening market is fragmented due to the presence of several companies operating globally as well as regionally. Some of the global players include Bio-Reference Laboratories Inc., Genova Diagnostics, Immundiagnostik AG, Quest Diagnostics, SpectraCell Laboratories Inc., and Telomere Diagnostics Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Applications of Cellular Health Screening in Personalized Medicine
    • 4.2.2 Increasing Government Focus on Preventive Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Risk Associated With the Transport of Samples
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Single-test Panels
      • 5.1.1.1 Telomere Tests
      • 5.1.1.2 Oxidative Stress Tests
      • 5.1.1.3 Inflammation Tests
      • 5.1.1.4 Heavy Metals Tests
    • 5.1.2 Multi-test Panels
  • 5.2 By Sample Type
    • 5.2.1 Blood Samples
    • 5.2.2 Urine Samples
    • 5.2.3 Other Sample Types
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bio-Reference Laboratories, Inc. (OPKO Health)
    • 6.1.2 Genova Diagnostics
    • 6.1.3 Immundiagnostik AG
    • 6.1.4 Laboratory Corporation of America Holdings
    • 6.1.5 Quest Diagnostics
    • 6.1.6 Segterra Inc.
    • 6.1.7 SpectraCell Laboratories Inc.
    • 6.1.8 Telomere Diagnostics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS